Efficacy and Safety of Indoor Residual Spray for Dengue Vector Control
This quasi-experimental interventional study was conducted over 1 year, from May 2024-May 2025 at Station Health Organization, Combined Military Hospital, Peshawar Cantonment. Two comparable localities in Peshawar Cantonment were selected based on previous dengue incidence reports. Non-Probability consecutive sampling technique was used. Prior approval was sought from Station Commander, Station Headquarters Peshawar to conduct the study in Peshawar Cantonment. Hospital ethical review certificate was obtained (vide CMH Peshawar Letter No: 00254/25). Written informed consent was taken from the participants for inclusion in the study. One locality was designated as the intervention area (Indoor Residual Spray applied), and the other as the control area (Indoor Residual Spray not applied). Households were selected using a non-probability consecutive sampling technique.
In the intervention area, indoor residual spraying was conducted using Deltamethrin 2.5% WP, following WHO guidelines. Spray teams were trained and monitored to ensure proper application on interior walls, dark corners, and mosquito resting sites. Spraying was repeated every three months.
Entomological surveys were conducted at baseline and monthly thereafter in both areas, using larval/pupal indices (House Index and Breteau Index). Adult mosquito density was measured using backpack aspirators and resting catches. Dengue case data was collected by the Station Health Organization from CMH Peshawar and cross-checked with the Pathology department of the same hospital. The study was conducted as pilot study of the organization.
Data was analyzed using Statistical Pacakage for Social Sceinces version 27. Mean mosquito density, larval indices, and dengue incidence were compared between intervention and control areas using paired t-test. A p-value < 0.05 was considered statistically significant.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi helyek
-
-
Khyber Pakhtunkhwa
-
Peshawar, Khyber Pakhtunkhwa, Pakisztán, 25000
- Station Health Organization C/O Combined Military Hospital Peshawar
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Households consenting to participate and allow entomological inspections.
- Permanent residents with no history of shifting during the study period.
Exclusion Criteria:
- Houses under construction or vacant.
- If any resident of the household had prior history of allergic reaction to the sprayed chemicals.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Megelőzés
- Kiosztás: Nem véletlenszerű
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: IRS Area
100 households were inducted in the IRS Arms |
In the intervention area, indoor residual spraying was conducted using Deltamethrin 2.5% WP, following WHO guidelines. Spray teams were trained and monitored to ensure proper application on interior walls, dark corners, and mosquito resting sites. Spraying was repeated every three months. |
|
Nincs beavatkozás: Control Area
100 households were inducted in the Control Arm |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
To assess the safety of indoor residual spray in terms of participants reported adverse side effects after the use of spray ; both immediate and up to 3 months folllow up
Időkeret: 3 months follow up to asses the safety of indoor residual spray
|
To assess the safety of indoor residual spray in terms of participants reported adverse side effects after the use of spray ; both immediate and up to 3 months folllow up. Patients will report any adverse effects to the investigator, including rhinitis, skin rash, urticaria or any other newer finding noticed by the participant. |
3 months follow up to asses the safety of indoor residual spray
|
|
To assess the efficacy of indoor residual spray using House Index
Időkeret: 3 months follow-up to assess the efficacy of indoor residual spray to kill the mosquitoes using changes in House Index.
|
The Efficacy of indoor residual spray was assessed using House Index. House Index was compared for interventional area where the indoor residual spray was performed and the control area which was intervention naive. The baseline and 3 months follow up indices were compared to ascertain the efficacy of intervention. The House Index (HI) is the percentage of inspected houses that have mosquito larvae or pupae in or around them |
3 months follow-up to assess the efficacy of indoor residual spray to kill the mosquitoes using changes in House Index.
|
|
The Efficacy of indoor residual spray was assessed using Bretau Index.
Időkeret: The baseline and 3-month follow-up indices were compared to ascertain the efficacy of intervention.
|
The Efficacy of indoor residual spray was assessed using Bretau Index. Bretau Index was compared for interventional area where the indoor residual spray was performed and the control area which was intervention naive. Bretau Index measures mosquito vector density by tracking the number of positive water-holding containers per 100 houses inspected |
The baseline and 3-month follow-up indices were compared to ascertain the efficacy of intervention.
|
Együttműködők és nyomozók
Szponzor
Publikációk és hasznos linkek
Általános kiadványok
- Bowman LR, Donegan S, McCall PJ. Is Dengue Vector Control Deficient in Effectiveness or Evidence?: Systematic Review and Meta-analysis. PLoS Negl Trop Dis. 2016 Mar 17;10(3):e0004551. doi: 10.1371/journal.pntd.0004551. eCollection 2016 Mar.
- Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res. 2002 Jul-Aug;33(4):330-42. doi: 10.1016/s0188-4409(02)00378-8.
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- 00254/25
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD terv leírása
Study protocol and statistical data analysis sheet/ methods will be shraed upon request
IPD megosztási időkeret
15 Sep 2026 to 15 Jun 2027
IPD-megosztási hozzáférési feltételek
Upon request, any one associated with heathcare system may be able to accesss the study protocol and any statistical data analysis format
Az IPD megosztását támogató információ típusa
- STUDY_PROTOCOL
- NEDV
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .